share_log

The Returns On Capital At Shandong Weigao Orthopaedic Device (SHSE:688161) Don't Inspire Confidence

The Returns On Capital At Shandong Weigao Orthopaedic Device (SHSE:688161) Don't Inspire Confidence

山东威高骨科器械(SHSE: 688161)的资本回报并不能激发信心
Simply Wall St ·  03/07 15:43

What are the early trends we should look for to identify a stock that could multiply in value over the long term? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. However, after investigating Shandong Weigao Orthopaedic Device (SHSE:688161), we don't think it's current trends fit the mold of a multi-bagger.

我们应该寻找哪些早期趋势来确定一只可能长期价值成倍增长的股票?首先,我们想找一个正在成长的 返回 关于已用资本(ROCE),然后除此之外,还不断增加 基础 所用资本的比例。简而言之,这些类型的企业是复合机器,这意味着他们不断以更高的回报率对收益进行再投资。但是,在调查了山东威高骨科器械(SHSE: 688161)之后,我们认为目前的趋势不符合多袋机的模式。

Return On Capital Employed (ROCE): What Is It?

资本使用回报率(ROCE):这是什么?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Shandong Weigao Orthopaedic Device, this is the formula:

对于那些不知道的人来说,ROCE是衡量公司年度税前利润(其回报率)的指标,相对于该业务使用的资本。要计算山东威高骨科设备的这个指标,公式如下:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

已动用资本回报率 = 息税前收益 (EBIT) ¥(总资产-流动负债)

0.032 = CN¥130m ÷ (CN¥5.2b - CN¥1.1b) (Based on the trailing twelve months to December 2023).

0.032 = 1.3亿元人民币 ÷(52亿元人民币-11亿元人民币) (基于截至2023年12月的过去十二个月)

Therefore, Shandong Weigao Orthopaedic Device has an ROCE of 3.2%. Ultimately, that's a low return and it under-performs the Medical Equipment industry average of 9.2%.

因此,山东威高骨科器械的投资回报率为3.2%。归根结底,这是一个低回报,其表现低于医疗设备行业9.2%的平均水平。

roce
SHSE:688161 Return on Capital Employed March 7th 2024
SHSE: 688161 2024 年 3 月 7 日动用资本回报率

In the above chart we have measured Shandong Weigao Orthopaedic Device's prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering Shandong Weigao Orthopaedic Device for free.

在上图中,我们将山东威高骨科设备先前的投资回报率与之前的表现进行了对比,但可以说,未来更为重要。如果你愿意,你可以免费查看分析师对山东威高骨科设备的预测。

So How Is Shandong Weigao Orthopaedic Device's ROCE Trending?

那么山东威高骨科设备的投资回报率走势如何?

In terms of Shandong Weigao Orthopaedic Device's historical ROCE movements, the trend isn't fantastic. To be more specific, ROCE has fallen from 22% over the last five years. And considering revenue has dropped while employing more capital, we'd be cautious. This could mean that the business is losing its competitive advantage or market share, because while more money is being put into ventures, it's actually producing a lower return - "less bang for their buck" per se.

就山东威高骨科器械的历史ROCE运动而言,这一趋势并不理想。更具体地说,投资回报率已从过去五年的22%下降。考虑到在雇用更多资本的同时收入有所下降,我们会谨慎行事。这可能意味着该企业正在失去其竞争优势或市场份额,因为尽管向风险投资投入了更多资金,但实际上产生的回报却较低——本身 “性价比更低”。

Our Take On Shandong Weigao Orthopaedic Device's ROCE

我们对山东威高骨科器械投资回报率的看法

We're a bit apprehensive about Shandong Weigao Orthopaedic Device because despite more capital being deployed in the business, returns on that capital and sales have both fallen. Long term shareholders who've owned the stock over the last year have experienced a 51% depreciation in their investment, so it appears the market might not like these trends either. With underlying trends that aren't great in these areas, we'd consider looking elsewhere.

我们对山东威高骨科器械有点担心,因为尽管向该业务投入了更多资金,但资本回报率和销售额都下降了。去年持有该股的长期股东的投资贬值了51%,因此看来市场可能也不喜欢这些趋势。由于这些领域的潜在趋势并不理想,我们会考虑将目光投向其他地方。

One more thing, we've spotted 2 warning signs facing Shandong Weigao Orthopaedic Device that you might find interesting.

还有一件事,我们发现了山东威高骨科设备面临的两个警告标志,你可能会觉得有趣。

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

对于那些喜欢投资稳健公司的人,可以查看这份资产负债表稳健和股本回报率高的公司的免费清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发